Kisspeptin-10 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Kisspeptin-10

Also known as: KP-10, Kp-10, Kiss-10, KiSS-10, metastatin-10

Endogenous neuropeptide / reproductive hormone (RF-amide family); C-terminal decapeptide fragment of kisspeptin-54, product of the KISS1 gene

Research chemicalLast updated: October 19, 2026Based on 30 peer-reviewed studies

What it is

Kisspeptin-10 is a reproductive hormone fragment used in fertility clinics as an alternative trigger for ovulation in IVF, and studied for testosterone management in men. It works by activating the chain of signals that tells the pituitary to release sex hormones. Investigational in humans; prohibited by WADA; used in clinical IVF research.

The scientific side

Kisspeptin-10 (KP-10) is the shortest biologically active C-terminal decapeptide derived from the KISS1 gene product. It binds to its cognate G-protein-coupled receptor GPR54 (also designated KISS1R) expressed on GnRH neurons in the hypothalamus (PMID 23550004; PMID 41062590; PMID 23550004). GPR54 activation by KP-10 causes long-lasting membrane depolarization of GnRH neurons through inhibition of inwardly rectifying and A-type K⁺ currents and activation of nonselective cation (TRPC) currents, thereby increasing GnRH pulse frequency and amplitude. The resultant GnRH secretion drives pituitary release of LH and FSH, and downstream gonadal sex steroid production (PMID 21632807; PMID 42549827). KP-10 thus sits at the apex of the hypothalamic-pituitary-gonadal (HPG) axis. Sex steroid feedback (negative and positive) modulates the sensitivity of GnRH neurons to kisspeptin input (PMID 22956346; PMID 23550011). Beyond the HPG axis, KP-10 signals through GPR54/FAK pathways to regulate collagen and glycosaminoglycan metabolism in cardiac fibroblasts (PMID 37968564; PMID 42159865), exerts antiangiogenic effects via inhibition of endothelial proliferation and migration, induces vasoconstriction and plasma extravasation in peripheral microvasculature, and has demonstrated anti-metastatic and pro-apoptotic activity in several cancer cell lines (PMID 41062590; PMID 25420482; PMID 38401763). Neuroprotective effects against α-synuclein-mediated apoptosis have also been reported through a GPR54-independent mechanism.

Class: Endogenous neuropeptide / reproductive hormone (RF-amide family); C-terminal decapeptide fragment of kisspeptin-54, product of the KISS1 gene

Administration & storage

Administration
Intravenous bolus injection (PMID: 21632807PMID: 30590872PMID: 21976724PMID: 22956346PMID: 35563582)Intravenous infusion (PMID: 42549827PMID: 21632807PMID: 21976724PMID: 35563582)Subcutaneous infusion (PMID: 42549827)Subcutaneous bolus injection (PMID: 21976724)Intraperitoneal injection (PMID: 38401763)Slow-release implant/formulation (PMID: 38401763)Intradermal injection (PMID: 21347414)
Storage
One anti-doping study noted that a black-market vial of KP-10 appeared to have undergone more degradation than a purchased reference standard, and that oxidation of the tryptophan residue to a kynurenine residue was identified as a degradation pathway; kinetic parameters were not fully elucidated. No specific storage conditions (temperature, light, duration) for research-grade or clinical KP-10 preparations were described in the reviewed abstracts.
Cautions
Rapid elimination: KP-10 has an estimated elimination half-life of approximately 30 minutes after injection in rats; human pharmacokinetic data are not described in the reviewed abstracts.,Degradation risk: KP-10 is susceptible to oxidation of its tryptophan residue to a kynurenine residue; a black-market vial showed greater degradation than a reference standard, indicating product quality concerns for non-pharmaceutical-grade material.,Dose-dependent adverse effects: High concentrations of KP-10 (10 µM) decreased cholinergic cell viability in vitro; a dose of 3 µg/kg IV bolus elicited a reduced LH response compared to 1 µg/kg in men, suggesting tachyphylaxis or receptor desensitization at higher doses.,Atherosclerosis risk signal: Prolonged KP-10 infusion in ApoE-knockout mice accelerated aortic atherosclerotic lesion development; cardiovascular safety in humans has not been established.,Endothelial senescence: KP-10 induced cellular senescence in human umbilical vein endothelial cells and impaired blood flow recovery in a rat ischemia model; implications for human vascular health are unknown.,WADA prohibited: KP-10 is included in the 2024 WADA Prohibited List due to testosterone-increasing potential; use by athletes constitutes a doping violation.,Sterile technique is required for any injectable preparation to prevent contamination (general safety principle; not specific to KP-10 from literature).

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Included in the 2024 World Anti-Doping Agency Prohibited List

Health Canada

Not stated in reviewed literature — requires manual verification